Table 2 The disease characteristics in the thoracotomy and VATS group
Variables | Thoracotomy (N = 67) | VATS (N = 14) | P value |
|---|---|---|---|
T stage before neoadjuvant chemotherapy | 0.135 | ||
1b | 0 (0) | 1 (7.1%) | |
1c | 1 (1.5%) | 2 (14.3%) | |
2a | 25 (37.3%) | 3 (21.4%) | |
2b | 7 (10.4%) | 2 (14.3%) | |
3 | 19 (28.4%) | 3 (21.4%) | |
4 | 15 (22.4%) | 3 (21.4%) | |
Clinical stage before neoadjuvant chemotherapy | 0.508 | ||
IIB | 13 (19.4%) | 1 (7.1%) | |
IIIA | 32 (47.8%) | 7 (50.0%) | |
IIIB | 22 (32.8%) | 6 (42.9%) | |
Neoadjuvant chemotherapy regimens | 0.664 | ||
Docetaxel + platinum | 16 (23.9%) | 2 (14.3%) | |
Paclitaxel + platinum | 16 (23.9%) | 3 (21.4%) | |
Gemcitabine + platinum | 35 (52.2%) | 9 (64.3%) | |
Cycles of neoadjuvant chemotherapy | 2 (1–5) | 2 (2–4) | 0.930 |
T stage after neoadjuvant chemotherapy | 0.058 | ||
0 | 1 (1.5%) | 1 (7.1%) | |
1b | 1 (1.5%) | 2 (14.3%) | |
1c | 0 (0) | 1 (7.1%) | |
2a | 42 (62.7%) | 8 (57.1%) | |
2b | 6 (9.0%) | 0 (0) | |
3 | 14 (20.9%) | 1 (7.1%) | |
4 | 3 (4.5%) | 1 (7.1%) | |
Clinical stage after neoadjuvant chemotherapy | 0.308 | ||
0 | 1 (1.5%) | 1 (7.1%) | |
IB | 15 (22.4%) | 4 (28.6%) | |
IIA | 1 (1.5%) | 0 (0) | |
IIB | 12 (17.9%) | 0 (0) | |
IIIA | 25 (37.3%) | 7 (50.0%) | |
IIIB | 12 (17.9%) | 2 (14.3%) | |
VI | 1 (1.5%) | 0 (0) | |
Response assessment | 0.261 | ||
cCR | 1 (1.5%) | 1 (7.1%) | |
PR | 43 (64.2%) | 11 (78.6%) | |
SD | 19 (28.4%) | 2 (14.3%) | |
PD | 4 (6.0%) | 0 (0) | |
T downstaging | 28 (41.8%) | 9 (64.3%) | 0.124 |
TNM downstaging | 29 (43.3%) | 8 (57.1%) | 0.344 |
Pathologic stage | 0.221 | ||
IA | 1 (1.5%) | 3 (21.4%) | |
IB | 22 (32.8%) | 3 (21.4%) | |
IIA | 2 (3.0%) | 0 (0) | |
IIB | 18 (26.9%) | 3 (21.4%) | |
IIIA | 18 (26.9%) | 4 (28.6%) | |
IIIB | 5 (7.5%) | 1 (7.1%) | |
VI | 1 (1.5%) | 0 (0) | |
Tumor size (cm)a | 3.1 (0.8–8.0) | 2.5 (1.0–7.0) | 0.335 |